Note to users. If you're seeing this message, it means that your browser cannot find this page's style/presentation instructions -- or possibly that you are using a browser that does not support current Web standards. Find out more about why this message is appearing, and what you can do to make your experience of our site the best it can be.

Science 4 November 1994:
Vol. 266. no. 5186, pp. 801 - 805
DOI: 10.1126/science.7973634
Prev | Table of Contents | Next

Articles

Science, Vol 266, Issue 5186, 801-805
Copyright © 1994 by American Association for the Advancement of Science

articles

Hydroxyurea as an inhibitor of human immunodeficiency virus-type 1 replication

F Lori, A Malykh, A Cara, D Sun, JN Weinstein, J Lisziewicz, and RC Gallo

Laboratory of Tumor Cell Biology, National Cancer Institute, National Institutes of Health, Bethesda, MD 20892-4255.

Hydroxyurea, a drug widely used in therapy of several human diseases, inhibits deoxynucleotide synthesis--and, consequently, DNA synthesis--by blocking the cellular enzyme ribonucleotide reductase. Hydroxyurea inhibits human immunodeficiency virus-type 1 (HIV-1) DNA synthesis in activated peripheral blood lymphocytes by decreasing the amount of intracellular deoxynucleotides, thus suggesting that this drug has an antiviral effect. Hydroxyurea has now been shown to block HIV-1 replication in acutely infected primary human lymphocytes (quiescent and activated) and macrophages, as well as in blood cells infected in vivo obtained from individuals with acquired immunodeficiency syndrome (AIDS). The antiviral effect was achieved at nontoxic doses of hydroxyurea, lower than those currently used in human therapy. Combination of hydroxyurea with the nucleoside analog didanosine (2',3'-dideoxyinosine, or ddl) generated a synergistic inhibitory effect without increasing toxicity. In some instances, inhibition of HIV-1 by hydroxyurea was irreversible, even several weeks after suspension of drug treatment. The indirect inhibition of HIV-1 by hydroxyurea is not expected to generate high rates of escape mutants. Hydroxyurea therefore appears to be a possible candidate for AIDS therapy.


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES:
Measles virus inhibits human immunodeficiency virus type 1 reverse transcription and replication by blocking cell-cycle progression of CD4+ T lymphocytes.
M. Garcia, X.-F. Yu, D. E. Griffin, and W. J. Moss (2008)
J. Gen. Virol. 89, 984-993
   Abstract »    Full Text »    PDF »
Hydroxyurea-Induced Leg Ulcers Treated With a Protease-Modulating Matrix.
M. Romanelli, V. Dini, and P. Romanelli (2007)
Arch Dermatol 143, 1310-1313
   Abstract »    Full Text »    PDF »
Hydroxyurea and Interleukin-6 Synergistically Reactivate HIV-1 Replication in a Latently Infected Promonocytic Cell Line via SP1/SP3 Transcription Factors.
R. M. Oguariri, T. W. Brann, and T. Imamichi (2007)
J. Biol. Chem. 282, 3594-3604
   Abstract »    Full Text »    PDF »
Human Immunodeficiency Virus Reactivation by Phorbol Esters or T-Cell Receptor Ligation Requires both PKC{alpha} and PKC{theta}.
S. A. Trushin, G. D. Bren, S. Asin, K. N. Pennington, C. V. Paya, and A. D. Badley (2005)
J. Virol. 79, 9821-9830
   Abstract »    Full Text »    PDF »
In Vitro Combination of Amdoxovir and the Inosine Monophosphate Dehydrogenase Inhibitors Mycophenolic Acid and Ribavirin Demonstrates Potent Activity against Wild-Type and Drug-Resistant Variants of Human Immunodeficiency Virus Type 1.
K. Borroto-Esoda, F. Myrick, J. Feng, J. Jeffrey, and P. Furman (2004)
Antimicrob. Agents Chemother. 48, 4387-4394
   Abstract »    Full Text »    PDF »
Mutations in the R2 Subunit of Ribonucleotide Reductase That Confer Resistance to Hydroxyurea.
J. L. Sneeden and L. A. Loeb (2004)
J. Biol. Chem. 279, 40723-40728
   Abstract »    Full Text »    PDF »
Early Detection of a Two-Long-Terminal-Repeat Junction Molecule in the Cytoplasm of Recombinant Murine Leukemia Virus-Infected Cells.
F. Serhan, M. Penaud, C. Petit, T. Leste-Lasserre, S. Trajcevski, D. Klatzmann, G. Duisit, P. Sonigo, and P. Moullier (2004)
J. Virol. 78, 6190-6199
   Abstract »    Full Text »    PDF »
Immunosuppressive drugs as an adjuvant to HIV treatment.
E. Fumero, F. Garcia, and J. M. Gatell (2004)
J. Antimicrob. Chemother. 53, 415-417
   Abstract »    Full Text »    PDF »
Rapamycin causes down-regulation of CCR5 and accumulation of anti-HIV {beta}-chemokines: An approach to suppress R5 strains of HIV-1.
A. Heredia, A. Amoroso, C. Davis, N. Le, E. Reardon, J. K. Dominique, E. Klingebiel, R. C. Gallo, and R. R. Redfield (2003)
PNAS 100, 10411-10416
   Abstract »    Full Text »    PDF »
Pharmacokinetics of Hydroxyurea in Plasma and Cerebrospinal Fluid of HIV-1-Infected Patients.
P. R. Gwilt, K. K. Manouilov, J. McNabb, and S. S. Swindells (2003)
J. Clin. Pharmacol. 43, 1003-1007
   Abstract »    Full Text »    PDF »
Induction of G1 cycle arrest in T lymphocytes results in increased extracellular levels of beta -chemokines: A strategy to inhibit R5 HIV-1.
A. Heredia, C. Davis, A. Amoroso, J. K. Dominique, N. Le, E. Klingebiel, E. Reardon, D. Zella, and R. R. Redfield (2003)
PNAS 100, 4179-4184
   Abstract »    Full Text »    PDF »
Development of Varicella-Zoster Virus Infection in Patients with Chronic Myelogenous Leukemia Treated with Imatinib Mesylate.
G. N. Mattiuzzi, J. E. Cortes, M. Talpaz, J. Reuben, M. B. Rios, J. Shan, D. Kontoyiannis, F. J. Giles, I. Raad, S. Verstovsek, et al. (2003)
Clin. Cancer Res. 9, 976-980
   Abstract »    Full Text »    PDF »
Molecular Characterization of Preintegration Latency in Human Immunodeficiency Virus Type 1 Infection.
T. C. Pierson, Y. Zhou, T. L. Kieffer, C. T. Ruff, C. Buck, and R. F. Siliciano (2002)
J. Virol. 76, 8518-8531
   Abstract »    Full Text »    PDF »
Complementary Antiviral Efficacy of Hydroxyurea and Protease Inhibitors in Human Immunodeficiency Virus-Infected Dendritic Cells and Lymphocytes.
G. Piccinini, A. Foli, G. Comolli, J. Lisziewicz, and F. Lori (2002)
J. Virol. 76, 2274-2278
   Abstract »    Full Text »    PDF »
Inhibition of Human Immunodeficiency Virus Type 1 Transcription by Chemical Cyclin-Dependent Kinase Inhibitors.
D. Wang, C. de la Fuente, L. Deng, L. Wang, I. Zilberman, C. Eadie, M. Healey, D. Stein, T. Denny, L. E. Harrison, et al. (2001)
J. Virol. 75, 7266-7279
   Abstract »    Full Text »    PDF »
In Vitro Hydroxyurea Decreases Th1 Cell-Mediated Immunity.
A. Weinberg (2001)
Clin. Vaccine Immunol. 8, 702-705
   Abstract »    Full Text »    PDF »
Exploitation of the Low Fidelity of Human Immunodeficiency Virus Type 1 (HIV-1) Reverse Transcriptase and the Nucleotide Composition Bias in the HIV-1 Genome To Alter the Drug Resistance Development of HIV.
J. Balzarini, M.-J. Camarasa, M.-J. Perez-Perez, A. San-Felix, S. Velazquez, C.-F. Perno, E. De Clercq, J. N. Anderson, and A. Karlsson (2001)
J. Virol. 75, 5772-5777
   Abstract »    Full Text »    PDF »
Zidovudine Phosphorylation Determined Sequentially over 12 Months in Human Immunodeficiency Virus-Infected Patients with or without Previous Exposure to Antiretroviral Agents.
P. G. Hoggard, J. Lloyd, S. H. Khoo, M. G. Barry, L. Dann, S. E. Gibbons, E. G. Wilkins, C. Loveday, and D. J. Back (2001)
Antimicrob. Agents Chemother. 45, 976-980
   Abstract »    Full Text »    PDF »
Control of SIV Rebound Through Structured Treatment Interruptions During Early Infection.
F. Lori, M. G. Lewis, J. Xu, G. Varga, D. E. Zinn Jr., C. Crabbs, W. Wagner, J. Greenhouse, P. Silvera, J. Yalley-Ogunro, et al. (2000)
Science 290, 1591-1593
   Abstract »    Full Text »
Diminished Human Immunodeficiency Virus Type 1 Reverse Transcription and Nuclear Transport in Primary Macrophages Arrested in Early G1 Phase of the Cell Cycle.
N. A. Kootstra, B. M. Zwart, and H. Schuitemaker (2000)
J. Virol. 74, 1712-1717
   Abstract »    Full Text »
Coping with and Recovering from Hydroxyurea-induced Replication Fork Arrest in Budding Yeast.
J.F.X. DIFFLEY, K. BOUSSET, K. LABIB, E.A. NOTON, C. SANTOCANALE, and J.A. TERCERO (2000)
Cold Spring Harb Symp Quant Biol 65, 333-342
   Abstract »    PDF »
Hydroxyurea Potentiates the Antiherpesvirus Activities of Purine and Pyrimidine Nucleoside and Nucleoside Phosphonate Analogs.
J. Neyts and E. De Clercq (1999)
Antimicrob. Agents Chemother. 43, 2885-2892
   Abstract »    Full Text »    PDF »
Hydroxyurea Enhances the Activities of Didanosine, 9-[2-(Phosphonylmethoxy)ethyl]adenine, and 9-[2-(Phosphonylmethoxy)propyl]adenine against Drug-Susceptible and Drug-Resistant Human Immunodeficiency Virus Isolates.
S. Palmer, R. W. Shafer, and T. C. Merigan (1999)
Antimicrob. Agents Chemother. 43, 2046-2050
   Abstract »    Full Text »    PDF »
Nonproductive Human Immunodeficiency Virus Type 1 Infection in Nucleoside-Treated G0 Lymphocytes.
Y. D. Korin and J. A. Zack (1999)
J. Virol. 73, 6526-6532
   Abstract »    Full Text »
Control of HIV despite the Discontinuation of Antiretroviral Therapy.
J. Lisziewicz, E. Rosenberg, J. Lieberman, H. Jessen, L. Lopalco, R. Siliciano, B. Walker, and F. Lori (1999)
N. Engl. J. Med. 340, 1683
   Full Text »
Suppression of Replication of Multidrug-Resistant HIV Type 1 Variants by Combinations of Thymidylate Synthase Inhibitors with Zidovudine or Stavudine.
W.-Y. Gao, D. G. Johns, M. Tanaka, and H. Mitsuya (1999)
Mol. Pharmacol. 55, 535-540
   Abstract »    Full Text »
Maintenance Antiretroviral Therapies in HIV-Infected Subjects with Undetectable Plasma HIV RNA after Triple-Drug Therapy.
D. V. Havlir, I. C. Marschner, M. S. Hirsch, A. C. Collier, P. Tebas, R. L. Bassett, J. P.A. Ioannidis, M.K. Holohan, R. Leavitt, G. Boone, et al. (1998)
N. Engl. J. Med. 339, 1261-1268
   Abstract »    Full Text »    PDF »
Antiretroviral Therapy for HIV Infection in 1998: Updated Recommendations of the International AIDS Society-USA Panel.
C. C. J. Carpenter, M. A. Fischl, S. M. Hammer, M. S. Hirsch, D. M. Jacobsen, D. A. Katzenstein, J. S. G. Montaner, D. D. Richman, M. S. Saag, R. T. Schooley, et al. (1998)
JAMA 280, 78-86
   Abstract »    Full Text »    PDF »
Progression to the G1b Phase of the Cell Cycle Is Required for Completion of Human Immunodeficiency Virus Type 1 Reverse Transcription in T Cells.
Y. D. Korin and J. A. Zack (1998)
J. Virol. 72, 3161-3168
   Abstract »    Full Text »    PDF »
A Bioavailability and Pharmacokinetic Study of Oral and Intravenous Hydroxyurea.
G. I. Rodriguez, J. G. Kuhn, G. R. Weiss, S. G. Hilsenbeck, J. R. Eckardt, A. Thurman, D. A. Rinaldi, S. Hodges, D. D. Von Hoff, and E. K. Rowinsky (1998)
Blood 91, 1533-1541
   Abstract »    Full Text »    PDF »
Inhibition of NF-kappa B and HIV-1 Long Terminal Repeat Transcriptional Activation by Inducible Nitric Oxide Synthase 2 Activity.
D. Sekkai, F. Aillet, N. Israel, and M. Lepoivre (1998)
J. Biol. Chem. 273, 3895-3900
   Abstract »    Full Text »    PDF »
Casein kinase II is a selective target of HIV-1 transcriptional inhibitors.
J. W. Critchfield, J. E. Coligan, T. M. Folks, and S. T. Butera (1997)
PNAS 94, 6110-6115
   Abstract »    Full Text »    PDF »
Long-term Suppression of HIV-1 by Hydroxyurea and Didanosine.
F. Lori, H. Jessen, A. Foli, J. Lisziewicz, and P. S. Matteo (1997)
JAMA 277, 1437-1438
   Abstract »    PDF »
Regulation of T4 Phage Aerobic Ribonucleotide Reductase. SIMULTANEOUS ASSAY OF THE FOUR ACTIVITIES.
S. P. Hendricks and C. K. Mathews (1997)
J. Biol. Chem. 272, 2861-2865
   Abstract »    Full Text »    PDF »
Hydroxyurea Induces the Gene Expression and Synthesis of Proinflammatory Cytokines In Vivo.
P. Navarra, U. Grohmann, G. Nocentini, G. Tringali, P. Puccetti, C. Riccardi, and P. Preziosi (1997)
J. Pharmacol. Exp. Ther. 280, 477-482
   Abstract »    Full Text »
Denying HIV Safe Haven.
W. C. Greene (1996)
N. Engl. J. Med. 334, 1264-1265
   Full Text »
Effect of Hydroxyurea on the Frequency of Painful Crises in Sickle Cell Anemia.
S. Charache, M. L. Terrin, R. D. Moore, G. J. Dover, F. B. Barton, S. V. Eckert, R. P. McMahon, D. R. Bonds, and The Investigators of the Multicenter Study of Hydr (1995)
N. Engl. J. Med. 332, 1317-1322
   Abstract »    Full Text »    PDF »


To Advertise     Find Products

Science. ISSN 0036-8075 (print), 1095-9203 (online)